Moderna’s COVID vaccine faces FDA scrutiny and funding cuts amid legal and safety debates, spotlighting its role in mRNA tech.
As of February 2026, the FDA, led by Dr. Vinay Prasad, has refused to review Moderna's new mRNA flu vaccine application, citing trial design issues, specifically the comparator vaccine used. Despite late-stage trials showing improved efficacy, the FDA demands comparison against a high-dose vaccine for seniors. Moderna plans to meet with regulators to clarify next steps. This decision reflects heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr., who has cut mRNA vaccine funding and rolled back vaccine recommendations.
A coalition of 14 states and Pennsylvania's governor has filed a lawsuit against HHS Secretary Robert F. Kennedy Jr., challenging recent changes to US vaccine policies, including the removal of several childhood vaccines and the replacement of expert advisory members. The case raises concerns over public health and scientific integrity.